Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $18.32 +0.55%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 6
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 6
Join SI Premium – FREE
Oppenheimer analyst Hartaj Singh upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Perform to Outperform with a price target of $180.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $131.70 yesterday.
You May Also Be Interested In
- Northland Upgrades Similarweb Ltd (SMWB) to Outperform
- JPMorgan Upgrades Grupo Aval (AVAL) to Neutral
- Oppenheimer Upgrades Intuitive Surgical (ISRG) to Outperform, 'Crowding Out Competitors Strategically Smart'
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
